Phase 1/2a trial of NK cell therapy SNK01 wins FDA clearance
NKGen Biotech plans to begin clinical testing of SNK01, a natural killer (NK) cell therapy being developed to treat neurodegenerative diseases, in people with Parkinson’s disease, the company announced. This follows a go-ahead by the U.S. Food and Drug Administration (FDA) for an investigational new drug (IND) application…